UAB Researchers Advance Multiple Myeloma Treatment With Immunotherapy Breakthrough
• The MajesTEC-3 clinical trial led by UAB researchers demonstrates that a new two-drug immunotherapy regimen can lead to long-lasting remission for multiple myeloma patients. • Over 83 percent of patients enrolled in the trial remain alive and progression-free three years after therapy, supporting approval of this potentially curative treatment. • The findings represent a significant advance for multiple myeloma, a blood cancer with limited treatment options historically.
uab.edu
